封面
市场调查报告书
商品编码
1179914

2022-2029 年全球结合疫苗市场

Global Conjugate Vaccine Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内(2022 年至 2029 年),结合疫苗的全球市场规模预计将以 9.5% 的复合年增长率增长。

结合疫苗是一种亚单位疫苗,以强抗原和弱抗原结合为载体,增强免疫系统对弱抗原的反应。 有针对传染病的结合疫苗。 一些细菌和病毒具有多醣外壳以逃避免疫系统。 如果免疫系统不成熟,就可以识别这些细菌,因为这些疫苗接种会引发免疫力和将生物体与独特的多醣外壳结合的反应。 结合疫苗的例子包括脑膜炎球菌疫苗、b 型流感嗜血桿菌 (Hib) 疫苗和预防脑膜炎的肺炎球菌疫苗。

市场动态

扩大脑膜炎球菌结合疫苗的许可、越来越多的主要参与者开发和引入肺炎球菌和脑膜炎球菌疫苗,以及疫苗接种计划意识的提高预计将在预测期内推动市场增长。已成为推动因素

FDA 批准结合疫苗的增加预计将推动市场的增长。

2022 年 12 月 28 日,辉瑞公司宣布美国食品药品监督管理局 (FDA) 已向该公司的研究性五价脑膜炎球菌候选疫苗 (MenABCWY) 提交生物製品许可申请 (BLA) 以供审查。宣布其已被接受了。 辉瑞公司提交 MenABCWY 以预防脑膜炎球菌病,这是由于 10-25 岁人群中最常见的血清群所致。 此外,GSK plc 将于 2022 年 10 月 17 日推出适用于 10 至 55 岁人群的 Menbeo,以预防由脑膜炎奈瑟球菌血清群 A、C、Y 和 W 引起的侵袭性脑膜炎球菌病。宣布 FDA 已经批准了一种新的製造工艺脑膜炎球菌(A、C、Y 和 W-135 组)低聚醣白喉 CRM197 结合疫苗。 Membeo One 小瓶製剂现在是一种即用型单剂量小瓶製剂,提高了医疗保健专业人员的便利性。 Menbeo One 小瓶展示最初将面向美国联邦政府客户提供,预计将于 2023 年年中更广泛地提供。 因此,上述因素有望在预测期内推动市场。

结合疫苗没有副作用预计会阻碍市场增长。

结合疫苗副作用小,即使发生也很轻微,具有恢復快的特点。 在大约 10% 的结合疫苗接种者中观察到常见的副作用,例如硬化、发红、注射部位肿胀、不适、中度发烧和超敏反应。 还观察到其他影响,但很少见且很快消散。 与所有药物和疫苗一样,对疫苗或其成分之一产生过敏反应的风险很小。 大多数过敏反应是轻微的(不超过皮疹),但在极少数情况下会发生过敏性休克。 因此,预计上述因素将在预测期内阻碍市场。

COVID-19 影响分析

冠状病毒大流行对结合疫苗市场产生了一定影响。 MenC 疫苗在 11 个州以及巴西北部和南部接种。 MenC 疫苗覆盖率下降是 COVID-19 大流行期间遇到的挑战之一,这可能导致巴西脑膜炎球菌感染率上升。 例如,研究期间共接种了14,832,054例丙型脑膜炎球菌结合疫苗,66.30%是2019年3月至2020年2月,3%是2020年。33.70%是5月至12月实施的。 根据检测到的统计显着步骤(分别为 26.98%、41.47%),COVID-19 大流行对北部和南部地区以及巴西 11 个州的 MenC 疫苗接种产生了负面影响。

另一方面,由于美国食品和药物管理局 (FDA) 在大流行期间增加了疫苗批准,全球结合疫苗市场扩大。 例如,, 辉瑞公司和 BioNTech S.E. 于 2021 年 8 月宣布美国食品和药物管理局 (FDA) 宣布 COMIRNATY(COVID-19 疫苗,mRNA)宣布已授予其生物製品许可证应用程序 (BLA)。 大量的申请数据,包括第二剂后 6 个月的疗效和安全性数据,作为批准的依据。 由于上述背景,该市场受到影响,未来有望进一步扩大。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

  • 市场影响因素
    • 司机
      • 由于 FDA 越来越多地批准结合疫苗,预计市场会增长。
    • 约束因素
      • 结合疫苗没有副作用,预计会阻碍市场增长。
    • 机会
    • 影响分析

第5章行业分析

  • 搬运工的五种力量
  • 供应链
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 单价结合疫苗
  • 多价结合疫苗

第8章疾病与适应症

  • 肺炎球菌
  • 流感
  • 脑膜炎球菌
  • 其他

第9章病原体类型

  • 细菌
  • 病毒式传播

第 10 章按患者类型分类

  • 儿科
  • 成人

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第13章公司简介

  • 葛兰素史克公司。
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Merck & Co. Inc.
  • Fablife
  • SutroVax Inc.
  • Sanofi Pasteur SA.
  • Pfizer
  • Sinovac Biotech Ltd.
  • IDT Biologics GmbH
  • GreenSignal Bio Pharma Limited
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic

第14章 全球结合疫苗市场-DataM

简介目录
Product Code: DMPH1515

Market Overview

The global conjugate vaccine market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.5% during the forecast period (2022-2029).

A conjugate vaccination is a subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen, increasing the immune system's response to the weak antigen. Conjugate vaccines for infectious diseases are available. Some bacteria and viruses have polysaccharide coats that allow them to evade the immune system. An immature immune system can recognize these bacteria when conjugate vaccines are used because these vaccinations connect the unique polysaccharide coats to an organism by eliciting immunity and reaction. Meningococcal vaccinations to prevent meningitis, the Haemophilus influenzae type B (Hib) vaccine, and the pneumococcal vaccine are all examples of conjugate vaccines.

Market Dynamics

Growing approval for the meningococcal conjugate vaccine, increasing key players for developing and introducing vaccines for pneumococcal and meningococcal vaccines, and rising awareness about vaccination programs are the factors to drive the market in the forecast period.

The increasing FDA approvals for conjugate vaccines are expected to drive market growth.

On December 28, 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY to prevent meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age. Additionally, on October 17, 2022, GSK plc announced that the FDA had approved a new formulation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation is now available in a ready-to-use single vial, making it more convenient for healthcare providers. The Menveo one-vial presentation will initially be available to federal customers in the United States, with broader availability expected in mid-2023. Thus, from the above factors, the market is expected to drive in the forecast period.

Fewer side effects of the conjugate vaccine are expected to hamper the market growth.

The conjugate vaccines have had few side effects; when they have occurred, they have been mild and resolved quickly. About 10% of persons getting conjugate vaccines have common side effects such as hardening, reddening, swelling where the injection is given, malaise, moderate fever, and irritability. Other effects have been observed, but they are uncommon and disappear quickly. There is a small risk of an allergic reaction to the vaccine or one of its components, as with all medicines and vaccines. Most allergic reactions are mild (a skin rash and nothing more), but in extremely rare cases, anaphylactic shock can occur. Hence, from the above factors, the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The coronavirus pandemic has moderately impacted the conjugate vaccine market. MenC vaccine doses were given out in 11 Brazilian states and Northern and Southern Brazil. Reduced MenC vaccine coverage is one of the difficulties encountered during the COVID-19 pandemic, and as a result, it may raise meningococcal infection rates in Brazil. For instance, 14,832,054 doses of the meningococcal C conjugate vaccination were delivered overall during the study period, with 66.30% occurring between March 2019 and February 2020 and 33.70% between March and December 2020. The COVID-19 pandemic had a negative effect on the number of MenC vaccine doses delivered in the North and South regions (26,98% and 41.47%, respectively), as well as in the eleven Brazilian States, according to statistically significant steps that were detected.

In contrast, the global market for conjugate vaccines has grown due to the U.S. FDA's (Food and Drug Administration) expanding vaccine approvals during the pandemic. For instance, Pfizer Inc. and BioNTech S.E. announced in August 2021 that the U.S. Food and Drug Administration (FDA) had approved the Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA), which is intended to prevent COVID-19 in people 16 years of age and older. A thorough submission package, which included six-month efficacy and safety data after the second dose, formed the foundation for the approval. Thus, from the above factors, the market got affected and is expected to boost in the forecast period.

Segment Analysis

Multivalent Conjugate Vaccine segment is expected to hold the largest market share in conjugate vaccine market

The multivalent conjugate vaccine segment accounted for the largest market share in 2021. The multivalent immunogenic conjugates are synthesized using hydrazide chemistry to conjugate mixtures of more than one polysaccharide (at the desired ratio) to at least one carrier protein. Moreover, multivalent conjugate vaccines are cost-effective, improve manufacturing efficiency, streamline the preparation of combined conjugate vaccines, and can also be used to conjugate mixtures of other reagents (peptides, therapeutic agents) to carrier proteins to create therapeutics and reagents compared to monovalent conjugate vaccines. Therefore, it has increased the demand for multivalent conjugate vaccines. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global conjugate Vaccine market

North America region accounted for the largest market share in 2021. The rise in the prevalence of the infectious disease, the increase in the initiatives by the government, the increasing FDA approvals for the conjugate vaccine, and the rising demand for meningococcal, pneumococcal vaccines and other conjugate vaccines are the factors to drive the market in the forecast period. For instance, On April 24, 2020, the FDA approved a Biologics License Application for the MenQuadfi Meningococcal Conjugate Vaccine to prevent invasive meningococcal disease in people two years older. MenQuadfi is a quadrivalent meningococcal vaccine that uses tetanus toxoid as a protein carrier in the United States. It is available in a ready-to-use liquid formulation, eliminating the need for vaccine reconstitution for healthcare providers. Additionally, On August 31, 2022, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as single booster dose at least two months following primary or booster vaccination. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the conjugate vaccine market are GlaxoSmithKline plc, Merck & Co. Inc., Fablife, SutroVax Inc., Sanofi Pasteur SA., Pfizer, Sinovac Biotech Ltd., IDT Biologics GmbH, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited and Bavarian Nordic.

On June 08, 2021, Pfizer Inc. announced that the FDA approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) to prevent invasive disease and pneumonia caused by the vaccine's 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults 18 years and older.

GlaxoSmithKline plc:

Overview:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Product Portfolio:

Infanrix hexa: Infanrix hexa is a vaccine used to protect babies and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib).

The global conjugate vaccine market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing FDA approvals for conjugate vaccines are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Fewer side effects of the conjugate vaccine are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Monovalent Conjugate Vaccines*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multivalent Conjugate Vaccine

8. By Disease Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 8.1.2. Market Attractiveness Index, By Disease Indication
  • 8.2. Pneumococcal*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Others

9. By Pathogen Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 9.1.2. Market Attractiveness Index, By Pathogen Type
  • 9.2. Bacterial*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Viral

10. By Patient Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.1.2. Market Attractiveness Index, By Patient Type
  • 10.2. Pediatric*
      • 10.2.1.1. Introduction
      • 10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Adults

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. GlaxoSmithKline plc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co. Inc.
  • 13.3. Fablife
  • 13.4. SutroVax Inc.
  • 13.5. Sanofi Pasteur SA.
  • 13.6. Pfizer
  • 13.7. Sinovac Biotech Ltd.
  • 13.8. IDT Biologics GmbH
  • 13.9. GreenSignal Bio Pharma Limited
  • 13.10. Taj Pharmaceuticals Limited
  • 13.11. Bavarian Nordic

LIST NOT EXHAUSTIVE

14. Global Conjugate Vaccine Market- DataM

  • 14.1. Appendix
  • 14.2. About Us
  • 14.3. Contact Us